At ASIF Ventures, we're thrilled to announce our investment in OASYS NOW, a pioneering force in the healthcare technology sector. OASYS NOW is dedicated to revolutionizing genomics and health data management, and we're excited to be a part of their journey.

The Problem:

OASYS addresses a critical need for drug development companies to bring their new medicine and treatments to market: finding suitable candidates for clinical trials and research studies. For many patients with life-threatening chronic and rare diseases, it is equally important to be informed about new treatment options as soon as they become available, which could potentially save their lives. However, currently, the process of finding the right patients and suitable treatments is done in very manual and laborious processes, which are inefficient and slow, costing millions of euros for the drug research organizations and many precious lives every year.

The Unique Solution:

OASYS NOW's innovative platform GRIP, which is developed in collaboration with partners in major academic medical centers, hospitals, and patient organizations, aims to tackle these challenges by acting as a digital Waiting Room for all patients waiting to receive new treatments as soon as they become available in clinical trials. Using GRIP, patients can take control of their electronic health records (EHR) and receive up-to-date information about the latest medicines and treatments available to them through clinical trials close to their homes.

Meet the Visionary Team:

Founded by Nima Salami, Sara Okhuijsen, and Viktor Koppenol, the diverse team brings expertise in genomics, data science, finance, operations, and technology—providing a powerhouse of knowledge to navigate the complexities of securing sensitive genomic data.

Impressive Traction:

OASYS NOW's achievements include winning startup competitions, a TED Talk, raising $285k in pre-seed funding, and raising 2-3M in Seed funding. They've secured LOIs from potential customers and are working with patient organizations, doctors, and various departments in hospitals across the Netherlands to help patients with cardiovascular diseases.

Market Opportunity:

OASYS NOW is tapping into a market that is projected to become a 86bn dollar market by 2030 and with a CAGR of 6.9%, the global clinical trial market offers immense potential. OASYS NOW's focus on patient-centric approach and use of insight generation technologies to speed up the access to medicine for patients, positions them strongly within the European market, showcasing significant growth opportunities.

ASIF Ventures was captivated by OASYS NOW's innovative approach, commitment to making personalized health accessible globally, by bringing precision medicine to patients faster, and strategic positioning within the burgeoning clinical trials market—a synergy aligned with our goal to foster impactful entrepreneurship.

ASIF Ventures' latest investment: OASYS NOW!